Business Context and Reporting Period
This Form 8-K is a current report filed by Palisade Bio, Inc. on April 19, 2022. The filing addresses Item 8.01 (Other Events) regarding the status of the Company's outstanding warrants and common stock.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only quantitative data provided relates to equity capitalization:
- Common Stock Outstanding: 18,233,479 shares as of April 19, 2022.
- Par Value: $0.01 per share.
- Trading Symbol: PALI (Nasdaq Capital Market).
Material Changes
The report details the full exercise of the Company's May 2021 Warrants:
- Warrant Details: Originally exercisable for 3,994,302 shares at an exercise price of $3.88.
- Exercise Activity:
- 2,700,000 warrants were exchanged via cashless exercise on February 2, 2022.
- 1,294,302 warrants were exchanged via cashless exercise on March 15, 2022.
- Current Status: The May 2021 Warrants are now fully exercised.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of warrant exercises. It refers investors to the Form 10-K filed on March 17, 2022, for a complete description of other outstanding common stock warrants.
Investor Verification Checklist
- Verify the total share count of 18,233,479 against the most recent Form 10-K or 10-Q.
- Confirm the status of other outstanding warrants referenced in the March 17, 2022 Form 10-K.
- Review the cashless exercise mechanics to understand the dilution impact on existing shareholders.